Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00638911
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use after market launch.
- Detailed Description
Study 502.465(NCT00638911) was planned and conducted as 6 independent substudies with varying country participation. One study database, a data management plan or a TSAP were not planned and do not exist which precludes baseline and outcome analyses.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33247
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Endpoints will be the change from baseline in mean systolic blood pressure. 4-24 Weeks
- Secondary Outcome Measures
Name Time Method Secondary Endpoints are clinical control of the BP and response rate. 4-24 Weeks Other secondary Endpoints will be discontinuations and tolerability. 4-24 Weeks